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Objectives: Functional (psychogenic or somatoform) symptoms are common in neurology clinics.
Cognitive-behavioral therapy (CBT) can be an effective treatment, but there are major obstacles
to its provision in practice. We tested the hypothesis that adding CBT-based guided self-help
(GSH) to the usual care (UC) received by patients improves outcomes.
Methods: We conducted a randomized trial in 2 neurology services in the United Kingdom. Outpa-
tients with functional symptoms (rated by the neurologist as “not at all” or only “somewhat” explained
by organic disease) were randomly allocated to UC or UC plus GSH. GSH comprised a self-help man-
ual and4half-hour guidance sessions. The primary outcomewas self-rated health on a5-point clinical
global improvement scale (CGI) at 3months. Secondary outcomesweremeasured at 3 and6months.
Results: In this trial, 127 participants were enrolled, and primary outcome data were collected for
125. Participants allocated to GSH reported greater improvement on the primary outcome (ad-
justed common odds ratio on the CGI 2.36 [95%confidence interval 1.17–4.74; p0.016]). The
absolute difference in proportion “better” or “much better” was 13% (number needed to treat was
8). At 6 months the treatment effect was no longer statistically significant on the CGI but was
apparent in symptom improvement and in physical functioning.
Conclusions: CBT-based GSH is feasible to implement and efficacious. Further evaluation is
indicated.
Classification of evidence: This study provides Class III evidence that CBT-based GSH therapy
improves self-reported general health, as measured by the CGI, in patients with functional neuro-
logic symptoms. Neurology® 2011;77:564–572
GLOSSARY
CBT  cognitive-behavioral therapy; CGI  clinical global improvement scale; CPS  change in presenting symptoms scale;
GSH  guided self-help; NNT  number needed to treat; OR  odds ratio; SF-12 Medical Outcomes Short Form 12-Item
Scale; UC usual care.
Many somatic symptoms such as pain, weakness, and dizziness are unexplained by organic disease.1
Such symptoms are referred to as “functional,” “psychogenic,” “medically unexplained,” or “soma-
toform,” although all these terms are problematic.2 These symptoms account for one-third of atten-
dance at medical clinics3,4 with neurology having one of the highest rates.4,5 The outcome after
medical consultation is poor.6,7 As with many conditions at the interface of neurology and psychia-
try, integrated approaches to patient management have been neglected.
We know that intensive cognitive-behavioral therapy (CBT) can reduce the symptoms, distress,
and disability of patients with functional symptoms.8 However, there are major obstacles to its
delivery in practice because patients often regard psychological treatment as inappropriate and refer-
ral to mental health services as unacceptable and CBT therapists may not be available in all commu-
nities. These obstacles could potentially be overcome: CBT could be adapted to directly address the
patients’ somatic concerns,9 it could be delivered in the neurology clinic, and it could be provided in
a self-help form (bibliotherapy). CBT-based self-help is effective for other conditions, such as de-
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pression, especially if combined with face-to-
face guidance as so-called guided self-help
(GSH).10 CBT-based GSH has not, however,
been evaluated as a treatment for functional
neurologic symptoms.
We aimed to test the hypothesis that adding
GSH to the usual care (UC) received by neurol-
ogy outpatients with functional symptoms
would produce a greater improvement in their
self-rated health at 3 months after randomization.
We also measured symptoms (physical and psy-
chological), functional illness beliefs, health anx-
iety, and satisfaction with care at 3 and 6months.
METHODS Standard protocol approvals, registra-
tion, and patient consents. Approval was obtained from the
Multi-Centre Research Ethics Committee for Scotland (05/
MRE00/96). All participating patients gave informed consent.
The trial was registered at www.controlled-trials.com (Interna-
tional Standard Randomized Controlled Trial Number Register
Identifier ISRCTN47705219).
Study design and setting. The study was a 2-arm parallel
group randomized controlled trial with patient-rated outcome
assessment at 3 months and at 6 months. The trial was con-
ducted in 2 regional Scottish National Health Service neurology
services (Edinburgh and Glasgow), which together serve a popu-
lation of approximately 4 million.
Participants and procedures. We included adult neurology
outpatients with functional symptoms identified by screening
and referred by their neurologist. Between February 2006 and
January 2007, we asked neurologists to rate the symptoms of all
patients attending general neurology clinics on the following
4-point Likert-type scale: To what extent do you think this pa-
tient’s symptoms are explained by organic disease?—not at all,
somewhat, largely, or completely—and to refer those with func-
tional symptoms (defined as not at all or only somewhat ex-
plained by organic disease) to the trial.
We gave referred patients a study information leaflet and an
appointment with a trial doctor, at which written consent was
obtained. We excluded patients who 1) were judged to be unable
to use GSH (significant cognitive impairment or unable to com-
prehend English), 2) required specialist psychiatric care (severe
psychiatric disorder, currently engaged in psychological or psy-
chiatric treatment, or suicide risk), or 3) had headache as their
only symptom (because of the key role of addressing analgesic
use in their management).
Randomization. We randomly assigned consenting patients
in a 1:1 ratio to either usual care alone or usual care plus GSH.
The randomization sequence was computer-generated and strat-
ified on 2 potentially prognostic variables: neurology service (Ed-
inburgh or Glasgow) and symptoms being not at all or at least
somewhat explained by organic disease. The trial doctors ob-
tained the treatment allocation only after providing each pa-
tient’s data to a remote telephone-based randomization system.
Treatment conditions. All participants received UC, which
was enhanced by communicating the psychiatric diagnoses made
during the assessment (for example, major depression) to the pa-
tient’s primary care doctor and neurologist. We recorded all treat-
ments received during the trial when outcome data were collected.
Participants could not be masked to treatment allocation.
UC alone. Participants allocated to UC received UC alone.
UC plus CBT-based GSH. We offered all participants allo-
cated to GSH a CBT-based self-help workbook and face-to-face
guidance sessions in its use, in addition to UC. CBT is a form of
psychological treatment that aims to improve patients’ physical
symptoms, emotional state, and functioning by helping them to
understand and, where necessary, change how they think about
and respond to their symptoms and life situation. We developed
the workbook using existing CBT-based self-help manuals for
depression and anxiety and refined it by piloting.11,12 The book
explained functional symptoms9,13 as changes in nervous system
functioning that were influenced by psychological and behav-
ioral factors rather than simply psychogenic factors.14 It also in-
cluded 1) an explanation of how functional symptoms are
diagnosed, 2) a description of common symptoms and the asso-
ciated anatomy, physiology, and psychology, and 3) self-
management techniques, such as ways to reduce unhelpful
thinking about and coping with symptoms. More details are
available from the authors.
Guidance sessions (maximum 4 half-hour sessions over 3
months) were given face-to-face (by telephone if the patient was
unable to attend the hospital) by either a nurse or a psychologist
(both trained in CBT) in accordance with a guidance manual. A
neuropsychiatrist (A.C.) provided regular supervision. We
audio-recorded all guidance sessions; a randomly selected 10%
sample was independently rated for adherence to the manual.
Data collection.We collected baseline data before randomiza-
tion and outcome data at 3 and 6 months after randomization
using mailed self-report questionnaires. Participants were re-
minded by telephone, and, if necessary, their questionnaire data
were obtained by dictation to a research assistant who was blind
to treatment allocation.
Measures. Baseline data. Demographic and clinical variables
(age, sex, marital status, employment status, nature, and dura-
tion of symptoms) were recorded at interview.
Psychiatric diagnoses were made using a semi-structured in-
terview based on the PRIME-MD.15
Symptom burden was measured using the Patient Health
Questionnaire (with sexual and menstrual items removed) to leave
13 items.16 Physical function was measured using the subscale of the
Medical Outcomes Short Form 12-Item Scale (SF-12).17
Anxiety and depression were measured using the Hospital
Anxiety and Depression Scale.18 Health anxiety was assessed us-
ing items from the Whiteley Index19; participants were asked to
answer yes or no to the following questions: Do you think there
is something seriously wrong with your body? Do you worry a
lot about your health?
Illness beliefs were assessed using items from the Illness Per-
ceptions Questionnaire20; participants were asked to indicate
how much they agreed with the following on a 5-point Likert
scale (strongly disagree to strongly agree): My symptoms are
likely to be permanent rather than temporary. My symptoms are
a mystery to me.
Outcome data. Self-rated global improvement measured at
3 months using the clinical global improvement scale (CGI) was
the primary outcome. This 5-point Likert scale asked partici-
pants to rate their general health as much worse, worse, un-
changed, better, or much better, compared with how it was at
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the time of their original appointment at the neurology clinic.
This simple scale has been found to correlate with other specific
outcomes in this population.6
The change in presenting symptoms scale (CPS) was mea-
sured using a similar scale, on which participants rated the
“symptoms for which you came to the clinic.”
Treatment received during the trial was determined by ask-
ing participants to list all treatments (talking treatments, medica-
tion, and other treatments) they had received. For participants
allocated to GSH, the number and duration of guidance sessions
were recorded by the therapists.
Participants’ satisfaction with the overall quality of their
treatment (poor, fair, very good, or excellent) and whether
they would recommend it to a friend (definitely not, probably
not, possibly, or definitely) was assessed using 4-point Likert
scales.
Finally, measures of symptom burden, physical function anxiety,
and depression were repeated at the outcome assessments.
Figure 1 Flow of patients
566 Neurology 77 August 9, 2011
Statistical analysis. A sample size of 130 was planned on the
basis of feasibility and provided 80% power at the 5% significance
level (2-sided) to detect a common odds ratio (OR) of 2.5, using a
proportional odds model. We performed all the analyses on an
intention-to-treat basis, including all randomly assigned patients for
whom outcome data were available. We adjusted for the service the
patient attended, for how explained the symptoms were by disease
(“not at all” or “somewhat”), and, where relevant, for the baseline
score. The primary efficacy evaluation was at 3 months. Because the
data on the primary outcomes were virtually complete (98%), only a
complete case analysis was performed.
Analysis of the CGI score was based on comparing the ran-
domized groups using a proportional odds model (which calcu-
lates the OR using all the scale response categories).21 For this
analysis, participants who reported feeling worse or much worse
and better or much better were combined to give 3 outcome
groupings per treatment arm (worse, same, or better). This anal-
ysis was repeated for the CGI at the 6-month follow-up and also
for CPS and patient satisfaction at 3 and 6 months.
For the quantitative outcome measures, the group means
were compared using analysis of covariance. Differences between
the groups in health anxiety questions were analyzed using bi-
nary logistic regression to estimate the odds of endorsing them.
We made no correction for clustering by therapist because
the main component of treatment was a standardized manual.
Indeed, because the majority (72%) of participants receiving
GSHwere seen by one therapist, there was little scope to investigate
or adjust for a clustering effect. No formal adjustment was made for
multiplicity of outcome measures because there was a prespecified
primary outcome measure (CGI score at 3 months), and the p val-
ues for all other outcomes were interpreted conservatively.
Table 1 Pretreatment demographic and









Edinburgh 49 (49) 50 (51)
Glasgow 14 (50) 14 (50)
Age, y, mean (SD) 44.2 (12.9) 40.9 (10.1)
Male sex, n (%) 18 (29) 19 (30)
Marital status, n (%)
Married/partner 37 (59) 31 (48)
Single 14 (22) 20 (31)
Divorced/separated 12 (19) 13 (20)
Employment status, n (%)
Workinga 30 (48) 39 (61)
Organicity rating, n (%)
Not at all explained 35 (56) 34 (53)
Somewhat explained 28 (44) 30 (47)
Duration of symptoms,
n (%)
<1 y 15 (24) 13 (20)
1–5 y 27 (43) 35 (55)
>5 y 21 (33) 16 (25)
Presenting symptoms,
n (%)b
Pins and needles/tingling 31 (49) 32 (50)
Pain 28 (44) 36 (56)
Numbness 29 (46) 23 (36)
Headache 21 (33) 21 (33)
Weakness 19 (30) 21 (33)
Dizziness 18 (29) 16 (25)
Fatigue 16 (25) 16 (25)
Tremor/shaking 8 (13) 11 (17)
Visual disturbance 8 (13) 12 (19)
Blackouts 7 (11) 5 (8)
Psychiatric diagnosis
(PRIME-MD), n (%)
Major depression 13 (21) 11 (17)
Panic disorder 42 (67) 40 (63)
Agoraphobia 3 (5) 4 (6)
Generalized anxiety
disorder
25 (40) 23 (36)
Major depression 13 (21) 11 (17)
Panic disorder 42 (67) 40 (63)
Medications, n (%)
Antidepressant 25 (40) 28 (44)
Opiate 26 (25) 15 (23)











7.2 (3.2) 7.4 (3.0)
Depression (HADS), mean
(SD)
6.8 (4.2) 6.4 (4.6)
Anxiety (HADS), mean (SD) 8.5 (4.7) 8.4 (4.1)
SF-12 Physical function,
mean (SD)c
48 (40) 56 (36)
Belief: Symptoms
permanent, mean (SD)
3.0 (1.2) 3.1 (1.1)
Belief: Symptoms a
mystery, mean (SD)
3.8 (1.0) 3.6 (1.1)
Health anxiety: Yes to
“think something seriously
wrong with my body,” n (%)
22 (35) 21 (33)
Health anxiety: Yes to
“worry a lot about my
health,” n (%)
52 (33) 53 (34)
Abbreviations: GSH  guided self-help; HADS  Hospital
Anxiety and Depression Scale; PHQ-15  Patient Health
Questionnaire; SF-12Medical Outcomes Short Form 12-
Item Scale.
a Patients were not working because of their health in all
but 2 cases.
b Patients could have1 presenting symptom; the 10most
common symptoms are shown.
c Number available: n  63 for usual care; n  63 for usual
care plus GSH.
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RESULTS Sample. Of the 3,057 patients who had
their symptoms rated by a neurologist, 492 (16.1%)
received a diagnosis of functional symptoms. The neu-
rologists referred 291 of these patients, of whom 170
attended for assessment. Of the 127 patients who were
recruited, 63 were randomly assigned to UC and 64 to
GSH (figure 1).
Baseline characteristics. Table 1 shows characteristics
of the participants at baseline. Seventy percent were
women, and the mean age was 43 years. An average of
2.5 symptoms was recorded per patient; the 10 most
common symptoms are shown in table 1. Nearly half of
the participants reported that they were not working for
health reasons, and three-fourths reported symptoms of
longer than 1 year in duration. Generalized anxiety
(38%) and panic (56%) were the most common psy-
chiatric diagnoses. There were no substantial differences
in baseline variables between treatment arms.
Treatment received. Participants in both treatment
arms attended their primary care doctor; a minority
were seen for repeat appointments by the neurologist.
Eight participants had received a new prescription for
antidepressants by 3 months and an additional 6 by 6
months.
UC alone. Of 14 new prescriptions for antide-
pressants, 11 were for participants in the UC
group. One participant receiving UC received
CBT outside the trial.
GSH. All participants allocated to GSH were given
the workbook, and 62 of 64 (97%) received at least one
session of guidance in its use. The first 46 were allocated
to one therapist and the remaining 18 to the other. The
mean number of sessions given was 3 (range 0–4) of
average duration 30 minutes. Only 5 sessions were con-
Table 2 Comparison of outcomemeasures between trial arms at 3months
Outcomemeasure
Usual care Usual careGSH
Treatment





Change in overall health
(CGI)
63 17 62 30 2.4 (1.2 to 4.7)a 0.016
Change in presenting
symptoms (CPS)
63 29 62 38 2.3 (1.2 to 4.6)a 0.014
No. Mean (SD) No. Mean (SD)
Symptom burden
(PHQ-13)
62 7.0 (3.0) 61 6.2 (3.3) 1.0 (1.7 to0.2)b 0.009
Depression (HADS) 61 7.3 (4.1) 61 6.0 (4.9) 0.8 (1.8 to 0.3)b 0.153
Anxiety (HADS) 60 8.2 (4.9) 56 6.6 (3.9) 1.1 (2.4 to 0.1)b 0.075
SF-12 Physical Function 62 50 (40) 60 60 (39) 4 (4 to 12)b 0.347
Belief symptoms are
permanent
61 3.4 (1.1) 61 3.2 (1.2) 0.2 (0.6 to 0.1)b 0.231
Belief symptoms are a
mystery
61 3.7 (1.1) 61 3.3 (1.4) 0.4 (0.8 to 0.0)b 0.059
No. Percentage “no” No. Percentage “no”
Health anxiety: Is there
something seriously
wrong with your body?
60 55 61 75 3.3 (1.3 to 8.6)c 0.012
Health anxiety: Do you
worry a lot about your
health?
61 44 61 64 3.4 (1.4 to 8.6)c 0.009
No.
Percentage “very














recommend to a friend
55 46 60 88 10.5 (4.6 to 24.3)a 0.001
Abbreviations: CGI clinical global improvement scale; CI confidence interval; CPS change in presenting symptoms scale;
GSH  guided self-help; HADS  Hospital Anxiety and Depression Scale; PHQ-15  Patient Health Questionnaire; SF-12 
Medical OutcomesShort Form12-ItemScale.
a Common odds ratio from proportional odds regression model, adjusted for center and organicity.
b Mean difference, adjusted for baseline, center, and organicity.
c Odds ratio from logistic regression model, adjusted for baseline, center, and organicity.
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ducted by telephone. Adherence to the therapists’ man-
ual was rated as good in 23 of 25 participants (92%).
Completeness of data. Only 2 patients had missing
data on the primary outcome. The percent missing
for each secondary measure is shown in the tables.
Data were collected by telephone from 14% (18 of
127) at 3 months and 22% (28 of 127) at 6 months.
Primary outcome. We report primary outcome data
in dichotomized form in table 2 and in complete
form in figure 2. Analysis of the CGI score at 3
months, using a proportional odds model, which
uses the whole scale, yielded an adjusted common
OR for an improved outcome with GSH of 2.36
(95% confidence interval [CI] 1.17–4.74; p 
0.016). There was an absolute difference of 13% be-
tween treatment arms in those categorized as better,
equivalent to a number needed to treat (NNT) of 8.
Secondary outcomes. Secondary outcomes at 3
months are reported in table 2. At 3 months, partici-
pants allocated to GSH reported a greater improve-
ment in presenting symptoms (adjusted common
OR 2.33, 95% CI 1.19–4.56; p  0.014) and a
reduced symptom burden (adjusted mean difference
0.99; 95% CI1.73 to0.25; p 0.009). There
were, however, no differences between treatment
arms in physical function, anxiety, or depression.
Health anxiety (concern that there is something seri-
ously wrong with your body and worry a lot about
your health) was lower in those allocated to GSH.
There were, however, no effects on beliefs about
health (symptoms are permanent and symptoms are
a mystery). Satisfaction with treatment received at 3
months was much greater for participants allocated
to GSH.
Secondary outcomes at 6 months are reported in
table 3. The adjusted common OR for an improved
outcome with GSH on the CGI was 1.45 (95% CI
0.75–2.83) and was no longer statistically significant
(p  0.27). However, participants allocated to GSH
continued to report a greater improvement in pre-
senting symptoms (adjusted common OR 2.31, 95%
CI 1.18–4.51; p  0.014) and now physical func-
tion (adjusted mean difference 11.05, 95% CI 3.03–
19.06; p 0.007). Health anxiety was no longer less
in those allocated to GSH, but the belief that the
symptoms are permanent was. Satisfaction with
treatment at 6 months remained much greater for
those allocated to GSH.
No unintended adverse effects of treatment were
observed.
DISCUSSION We found that addition of GSH to
UC improved subjective health at 3 months more
than UC alone did. The treatment effect was of mod-
erate size with a 13% difference between treatment
arms in participants rating themselves as better or
much better (corresponding to a NNT of 8). Tak-
ing these results together with the greater improve-
ments in presenting symptoms, reduced symptom
burden, less health anxiety and greater satisfaction
with care, the chronicity of the patients’ illnesses,
and the simplicity of the intervention and its
safety, we believe that the observed treatment ef-
fect is clinically useful.
At the 6-month follow-up, the additional effect of
GSH on improvement in subjective health was
smaller (OR 1.45) and no longer statistically signifi-
cant. There was, however, a greater improvement in
presenting symptoms, less belief in the symptoms be-
ing permanent, greater satisfaction with care, and a
clinically significant 11-point difference on the
SF-12 physical functioning scale.22 The smaller treat-
ment effect on the primary outcome at follow-up
suggests that future studies should test the effect of
adding a maintenance phase to the GSH guidance.
There are limitations to this study. Although the
sample of patients recruited was identified by screen-
ing and therefore more likely to be representative of
patients attending neurology clinics than of referrals,
the proportion reported as having functional symp-
toms (16%) was smaller and the severity of their ill-
Figure 2 Self-rated change in overall health (CGI). Relative frequencies and
treatment group at 3 and 6months
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ness was greater than expected from previous
surveys.5,23 This finding suggests that neurologists
were selecting which patients to refer. We included
patients with a variety of symptoms, and the result-
ing heterogeneity potentially obscures the size of the
treatment effect for individual symptoms. Although
there is always a lack of certainty that symptoms are
definitely functional and not indicative of organic
disease, follow-up evidence from the same services
suggests that the diagnosis is rarely wrong.23 Even if
organic disease subsequently emerges, as long as
GSH is given as a supplement to rather than as a
replacement for UC, no harm is likely to result. The
UC given to participants in the trial was enhanced by
informing the patients’ primary care doctors of the
outcome of the psychiatric assessment. Although the
clinicians who provided GSH were trained in CBT,
we know from adherence ratings of session record-
ings that they provided only guidance and not CBT.
Because participants allocated to GSH received a
complex intervention of workbook, attention, and
face-to-face guidance sessions, we cannot identify
which of these components was the most important.
Our outcomes were measured by self-report, reflect-
ing the subjective nature of the problems we were
treating. However, the nature of the treatments
meant that participants could not be blinded to their
allocation, which could have potentially biased their
outcome ratings. Finally, the follow-up period was
relatively short, given the chronicity of the patients’
illnesses. Future effectiveness studies should examine
longer-term outcomes as well as costs.
There are many uncertainties about how best to
manage this large and important group of patients.
First, what should the treatment be? Whereas inten-
sive psychologically oriented CBT is effective for pa-
Table 3 Comparison of outcomemeasures between trial arms at 6-month follow-up
Outcomemeasure








Change in overall health
(CGI)
62 27 63 38 1.5 (0.7 to 2.8)a 0.269
Change in presenting
symptoms (CPS)
62 30 63 47 2.3 (1.2 to 4.5)a 0.014
No. Mean (SD) No. Mean (SD)
Symptom burden
(PHQ-13)
60 6.3 (2.9) 56 5.9 (3.3) 0.7 (1.5 to 0.1)b 0.076
Depression (HADS) 60 7.1 (4.1) 56 5.5 (5.7) 1.0 (2.2 to 0.2)b 0.105
Anxiety (HADS) 60 8.2 (4.9) 56 6.6 (3.9) 1.4 (2.7 to0.2)b 0.028
SF-12 Physical Function 60 50 (41) 55 68 (36) 11 (3 to 19)b 0.008
Belief symptoms are
permanent
60 3.5 (1.1) 56 3.1 (1.3) 0.5 (0.9 to0.1)b 0.024
Belief symptoms are a
mystery
59 3.5 (1.3) 56 3.1 (1.5) 0.3 (0.8 to 0.2)b 0.199
No. Percentage “no” No. Percentage “no”
Health anxiety: Is there
something seriously
wrong with your body?
60 60 56 70 1.8 (0.7 to 4.6)c 0.222
Health anxiety: Do you
worry a lot about your
health?
60 55 56 61 1.7 (0.7 to 3.9)c 0.253
No.
Percentage “very














recommend to a friend
50 46 54 80 9.6 (4.1 to 22.6)a 0.001
Abbreviations: CGI  clinical global improvement scale; CI  confidence interval; CPS  change in presenting symptoms
scale; GSH  guided self-help; HADS  Hospital Anxiety and Depression Scale; PHQ-13  Patient Health Questionnaire;
SF-12Medical Outcomes Short Form 12-Item Scale.
a Common odds ratio from proportional odds regression model, adjusted for center and organicity.
b Mean difference, adjusted for baseline, center, and organicity.
c Odds ratio from logistic regression model, adjusted for baseline, center, and organicity.
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tients with functional symptoms who seek it,24,25 we
have found that CBT based on a functional explana-
tion can be acceptable to relatively unselected neurol-
ogy patients. Second, where should treatment be
delivered? Although most previous studies have in-
cluded only patients willing to attend mental health
services,26–28 this trial shows that treatment can be
provided in neurology clinics.29 Third, who should
deliver treatment? CBT delivered by trained thera-
pists is expensive to provide, and therapists may sim-
ply not be available. Primary care physicians can be
trained to provide psychological treatment for func-
tional symptoms, but this has been found to be of
limited efficacy, in part because of the difficulty of
delivering it in routine practice30,31; treatment by
medical specialists is likely to have similar limita-
tions. This trial suggests that CBT given as GSH
offers a potentially widely available, effective, and
cost-effective treatment for the large number of neu-
rology patients with functional symptoms.
This trial provides initial evidence that CBT-
based GSH for neurology patients with functional
symptoms is feasible to deliver and acceptable to the
patients and produces better outcomes than UC
alone, at least in the short term. It therefore offers a
novel and potentially useful first step in improving
the management of functional symptoms. Further
development of this form of treatment to increase its
effectiveness and to evaluate its cost-effectiveness is
required. We also hope that this trial encourages oth-
ers in interdisciplinary treatment research for pa-
tients with this problem.
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